What happened
JW Lifescience filed provisional (unaudited) separate results for Q2 2026: revenue of US$40M (−0.8% year on year), operating profit of US$5.54M (+3.76% year on year) and net income of US$4.2M (−37.23% year on year).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$40M |
|---|---|
| Revenue vs a year earlier | −0.8% |
| Operating profit | US$5.54M |
| Net income | US$4.2M |
| Period | Q2 2026 (separate) |
| Filed | 2026-08-12, Operating results (preliminary) (fair disclosure) |
| Source | DART rcept 20260812800461 → open original filing |
Source: DART. Information only, not investment advice.